Get the Stockscreener App
8.70
0.23%
0.02
After Hours:
8.74
0.04
+0.46%
Novavax Inc stock is traded at $8.70, with a volume of 5.80M.
It is up +0.23% in the last 24 hours and up +7.94% over the past month.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.
See More
Previous Close:
$8.68
Open:
$8.59
24h Volume:
5.80M
Relative Volume:
1.02
Market Cap:
$1.39B
Revenue:
$793.74M
Net Income/Loss:
$-398.71M
P/E Ratio:
-1.1983
EPS:
-7.26
Net Cash Flow:
$-514.43M
1W Performance:
-4.50%
1M Performance:
+7.94%
6M Performance:
-38.12%
1Y Performance:
+77.19%
1-Day Range:
$8.37
$8.8877
1-Week Range:
$8.37
$9.75
52-Week Range:
$3.5324
$23.86
Novavax Inc Stock (NVAX) Company Profile
Name
Novavax Inc
Sector
Industry
Phone
240-268-2000
Address
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
Compare NVAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
8.70 | 1.39B | 793.74M | -398.71M | -514.43M | -3.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-10-24 | Upgrade | BofA Securities | Underperform → Neutral |
| May-10-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-09-23 | Upgrade | B. Riley Securities | Neutral → Buy |
| Apr-20-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Mar-01-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-09-23 | Reiterated | B. Riley Securities | Buy |
| Dec-30-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-02-22 | Initiated | Jefferies | Hold |
| Sep-22-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-20-22 | Initiated | BofA Securities | Underperform |
| Feb-23-22 | Reiterated | B. Riley Securities | Buy |
| Feb-22-22 | Resumed | Jefferies | Buy |
| Jan-21-22 | Initiated | Cowen | Outperform |
| May-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Aug-06-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-20 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
| Jul-16-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-29-20 | Reiterated | B. Riley FBR | Buy |
| Jun-29-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-05-20 | Upgrade | JP Morgan | Underweight → Neutral |
| May-28-20 | Reiterated | B. Riley FBR | Buy |
| May-12-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-27-19 | Resumed | B. Riley FBR | Buy |
| Aug-14-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-28-19 | Downgrade | Piper Jaffray | Overweight → Underweight |
| Dec-18-18 | Initiated | Ladenburg Thalmann | Buy |
| Dec-11-18 | Initiated | Oppenheimer | Outperform |
| Nov-26-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-21-18 | Upgrade | JP Morgan | Underweight → Overweight |
| Mar-29-18 | Upgrade | Seaport Global Securities | Neutral → Buy |
View All
Novavax Inc Stock (NVAX) Latest News
NVAX Starts Late-Stage Study on COVID-19-Flu Combo & Flu Vaccines - MSN
Novavax Inc. stock rises Friday, still underperforms market - MarketWatch
Peering Into Novavax's Recent Short Interest - Benzinga
(NVAX) Trading Advice - Stock Traders Daily
Wellington Management Group LLP Makes New $923,000 Investment in Novavax, Inc. (NASDAQ:NVAX) - MarketBeat
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch
Novavax adjusts vaccine deal with Australian government - Investing.com
Novavax Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Barclays PLC Raises Stock Position in Novavax, Inc. (NASDAQ:NVAX) - MarketBeat
Novavax Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Novavax, Inc. (NASDAQ:NVAX) Shares Fly 26% But Investors Aren't Buying For Growth - Simply Wall St
Novavax, Inc. (NASDAQ:NVAX) Shares Acquired by State Street Corp - MarketBeat
Notable Monday Option Activity: AVAV, NKE, NVAX - Nasdaq
Adult Vaccines Market Generated Opportunities, Future Scope - openPR
Novavax, Inc. (NASDAQ:NVAX) Shares Sold by Tidal Investments LLC - MarketBeat
Novavax Earns $50 Million from Sanofi Partnership - Precision Vaccinations
Novavax Advances Corporate Growth Strategy Through Sanofi Partnership, Including Achievement of First $50 Million Milestone - Quantisnow
Novavax to Participate in Jefferies London Healthcare Conference - The Eastern Progress Online
Novavax Cut Its Outlook Despite Beating Third-Quarter Forecasts. Is It A Sell In December 2024? - Investor's Business Daily
Novavax achieves $50M milestone in Sanofi partnershi - Investing.com
Why Is Novavax (NVAX) Up 13.6% Since Last Earnings Report? - Yahoo Finance
Institutional investors control 53% of Novavax, Inc. (NASDAQ:NVAX) and were rewarded last week after stock increased 6.3% - Yahoo Finance
Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4) - The Eastern Progress Online
Novavax Inc. stock rises Wednesday, still underperforms market - MarketWatch
Novavax to Participate in Upcoming September Conferences - The Eastern Progress Online
Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza - Quantisnow
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know - MSN
Novavax starts Phase 3 trial for dual COVID-19/flu vaccine - Investing.com
Novavax Launches Phase 3 Trial for Revolutionary COVID-Flu Combo Vaccine in Elderly Population - StockTitan
Novavax 2024-2025 Formula COVID-19 Vaccine Available at Major Pharmacies Across the U.S. - The Eastern Progress Online
Cramer's Lightning Round: 'I'm not a fan of Novavax' - CNBC
Two Sigma Advisers LP Grows Stake in Novavax, Inc. (NASDAQ:NVAX) - MarketBeat
Novavax, Inc. (NASDAQ:NVAX) Holdings Lowered by BNP Paribas Financial Markets - MarketBeat
Charles Schwab Investment Management Inc. Boosts Stock Position in Novavax, Inc. (NASDAQ:NVAX) - MarketBeat
Update on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial - The Eastern Progress Online
Novavax (NASDAQ:NVAX) Trading 10.1% HigherShould You Buy? - MarketBeat
Stock Traders Buy High Volume of Novavax Call Options (NASDAQ:NVAX) - MarketBeat
Deal Dispatch: Ubisoft In Buyout Talks, Dental Supplier Explores Sale, Beloved Drive-Through Goes Bankrupt - Benzinga
FY2024 EPS Estimates for Novavax Decreased by Zacks Research - MarketBeat
Novavax 2024-2025 Formula COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S. - The Eastern Progress Online
Noteworthy Friday Option Activity: NVAX, MTDR, MU - Nasdaq
Protecting Life-Saving IP: Novavax Strengthens Security with Threat Intelligence-Driven Security - Recorded Future
Novavax (NVAX) Shares Surge as Czech Facility Sold to Novo Nordi - GuruFocus.com
Institutional investors may overlook Novavax, Inc.'s (NASDAQ:NVAX) recent US$51m market cap drop as long-term gains remain positive - Simply Wall St
Novavax Inc. stock remains steady Thursday, still outperforms market - MarketWatch
Novavax to Sell Czech Manufacturing Plant to Novo Nordisk for $200M - Yahoo Finance
Novavax Cut Its Outlook Despite Beating Third-Quarter Forecasts. Is It A Sell? - Yahoo! Voices
2 Beaten-Down "Pandemic Stocks" to Consider for Contrarian Investors - AOL
Novo expands EU footprint with $200m Novavax plant - BioProcess Insider
Novavax Inc Stock (NVAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):